- Co-ultramicronized PEA plus the flavonoid luteolin (branded Glialia in clinical research) is the most-studied version of “PEA stacking” in human trials, not a marketing combination
- A randomized placebo-controlled trial found PEA-LUT improved smell recovery in patients with persistent post-COVID-19 olfactory loss[1]
- A 250-patient clinical study found significant gains in cognitive, motor, and pain measures in stroke patients using co-ultramicronized PEA-LUT during neurorehabilitation[2]
- Most PEA-LUT research targets neuroinflammation, not the musculoskeletal pain conditions covered elsewhere on this site, so the evidence base is different from PEA alone
Anyone who has looked closely at PEA supplement labels has probably noticed luteolin showing up as a co-ingredient more often than any other compound. This isn’t a random pairing chosen to make a label look more sophisticated. Co-ultramicronized PEA plus luteolin, sometimes shortened to PEA-LUT, is a specific, patented formulation (marketed clinically as Glialia) that has its own separate body of randomized trials, distinct from the plain-PEA research covered in most of this site’s other articles.
What Luteolin Adds
Luteolin is a flavonoid antioxidant found in foods like celery, thyme, and green peppers. On its own it has modest anti-inflammatory and antioxidant activity. Combined with PEA at a 10:1 ratio by mass and co-processed into a single ultramicronized particle (rather than two separate compounds mixed together), researchers have found the pairing performs better in neuroinflammation models than either compound does alone[3]. The theory is that luteolin’s antioxidant action complements PEA’s mast-cell-calming action, and the co-micronization step improves how well both compounds are absorbed together.
The Post-COVID Olfactory Research
The clearest recent clinical evidence for PEA-LUT comes from long COVID research. A multi-center, double-blinded, randomized, placebo-controlled trial gave patients with persistent smell loss (more than six months after testing negative for SARS-CoV-2) either daily ultramicronized PEA-LUT supplementation plus olfactory training, or olfactory training with a placebo. The PEA-LUT group showed meaningfully better recovery of smell function than the training-plus-placebo group[1]. This matters because it’s one of the few PEA-related trials targeting a specific, measurable, non-pain outcome (sense of smell) rather than a subjective pain score, which makes the result somewhat easier to verify objectively.
The Stroke Rehabilitation Data
The largest human dataset on PEA-LUT comes from a stroke recovery study. Researchers tracked 250 stroke patients undergoing neurorehabilitation, all treated for 60 days with the branded co-ultramicronized PEA-LUT preparation (700 mg PEA and 70 mg luteolin, taken sublingually twice daily) alongside their standard rehab therapy. Across neurological status, cognitive testing, spasticity, pain, and independence in daily activities, every measured index showed a statistically significant improvement from baseline to the 30-day mark[2]. This wasn’t a placebo-controlled trial in the strictest sense (patients were tracked against their own baseline, not a separate control arm), so it’s supportive rather than definitive evidence, but the sample size (250 patients) is unusually large for PEA research of any kind.
Where This Research Doesn’t Apply
It’s worth being direct about scope: the strongest PEA-LUT evidence is in neuroinflammatory and neurological contexts, post-COVID olfactory loss, stroke rehabilitation, and preclinical work in spinal cord injury and Alzheimer’s models[3]. That’s a different evidence base from the chronic pain, fibromyalgia, and neuropathy research covered in most of this site’s PEA content, which typically uses PEA alone or at different micronization levels. Someone taking a PEA-luteolin combo product for joint or nerve pain is relying on PEA’s general anti-inflammatory mechanism, not on the specific trials described above, since none of those trials tested musculoskeletal pain outcomes.
Practical Notes
Co-ultramicronized PEA-LUT products are typically dosed lower on the PEA side than standalone PEA supplements aimed at pain (the clinical stroke research used 700 mg PEA plus 70 mg luteolin daily, split into two doses). Anyone considering a PEA-luteolin product specifically for its studied indications (post-viral smell loss, neurological recovery support) should look for products that specify co-ultramicronization, since that processing step is what the clinical trials actually used, not simply PEA and luteolin capsules combined without that manufacturing step.
FAQ
What does adding luteolin to PEA actually do?
Luteolin is an antioxidant flavonoid that, when co-ultramicronized with PEA at a 10:1 ratio, has shown better results in neuroinflammation research than PEA alone in preclinical models[3].
Is there human evidence for PEA-luteolin, or just animal studies?
Both. A placebo-controlled human trial in post-COVID smell loss and a 250-patient stroke rehabilitation study are the two largest pieces of human evidence[1][2].
Does PEA-luteolin research apply to joint or nerve pain the way plain PEA research does?
Not directly. The PEA-LUT trials focus on neuroinflammatory conditions like post-viral olfactory loss and stroke recovery, not musculoskeletal pain.
Does the luteolin need to be co-ultramicronized with the PEA to match the research?
Yes, the clinical trials used a co-processed, single-particle formulation, not PEA and luteolin as two separately manufactured ingredients simply combined in one capsule.
References
- D’Ascanio L, Vitelli F, Cingolani C, Maranzano M, Brenner MJ, Di Stadio A. Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combined with Olfactory Training to Treat Post-COVID-19 Olfactory Impairment: A Multi-Center Double-Blinded Randomized Placebo-Controlled Clinical Trial. Eur Rev Med Pharmacol Sci. 2021;25(11):4156-4162. PMID 34156697
- Caltagirone C, Cisari C, Schievano C, et al. Co-ultramicronized Palmitoylethanolamide/Luteolin in the Treatment of Cerebral Ischemia: from Rodent to Man. Transl Stroke Res. 2016;7:54-69. PMID 26706245
- Cristiano C, et al. Beneficial Effects of Co-Ultramicronized Palmitoylethanolamide/Luteolin in a Mouse Model of Autism and in a Case Report of Autism. CNS Neurol Disord Drug Targets. 2016. PMID 27701827
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
